Chimeric Degraders of Cyclin Dependent Kinase 9 with Potential Use for Cancer Therapy

This technology revolves around bifunctional compounds designed to both bind cyclin-dependent kinase 9 (CDK9) and facilitate targeted ubiquitination, leading to the degradation of CDK9. These compounds are particularly effective in binding CDK9, a protein implicated in various cancers, and promoting its degradation by recruiting an E3 ubiquitin ligase, such as Cereblon or VHL. The E3 ubiquitin ligase tags CDK9 for proteasomal degradation. This invention presents methods for treating cancer and for promoting CDK9 protein degradation through E3 ubiquitin ligase activity in a subject or biological sample by administering the described compounds or compositions.